MicroRNAs in diseases and drug response

Current Opinion in Pharmacology

Volumn 8, Issue 5, 2008, Pages 661-667

  Garofalo, Michela ^a   Condorelli, Gerolama ^b   Croce, Carlo Maria ^a  

^a Department of Molecular Virology Immunology and Medical Genetics ^*  (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSPORTER; BETA SECRETASE; CISPLATIN; CYCLOPHOSPHAMIDE; DIHYDROFOLATE REDUCTASE; DOXORUBICIN; GAP JUNCTION PROTEIN; INWARDLY RECTIFYING POTASSIUM CHANNEL; METHOTREXATE; MICRORNA; NEW DRUG; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSCRIPTION ELONGATION FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PITX3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ALZHEIMER DISEASE; CAENORHABDITIS ELEGANS; CANCER CELL CULTURE; CELL SURVIVAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HEART ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER DYSFUNCTION; MALIGNANT NEOPLASTIC DISEASE; MYOPATHY; NONHUMAN; OVARY CANCER; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; TREATMENT OUTCOME;

ANIMALS; DISEASE; HUMANS; MICRORNAS; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA PROCESSING, POST-TRANSCRIPTIONAL;

EID: 54949158061     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.06.005     Document Type: Review

References (53)

1. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004) 281-297
2. He L., and Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5 (2004) 522-531
3. Lee Y., Ahn C., Han J., Choi H., Kim J., Yim J., Lee J., Provost P., Rådmark O., Kim S., et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 425 (2003) 415-419
4. Cai X., Hagedorn C.H., and Cullen B.R. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 10 (2004) 1957-1966
5. Lund E., Güttinger S., Calado A., Dahlberg J.E., and Kutay U. Nuclear export of microRNA precursors. Science 303 (2004) 95-98
6. Bernstein E., Caudy A.A., Hammond S.M., and Hannon G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409 (2001) 363-366
7. Hammond S.M., Boettcher S., Caudy A.A., Kobayashi R., and Hannon G.J. Argonaute2, a link between genetic and biochemical analyses of RNAi. Science 293 (2001) 1146-1150
8. Lewis B.P., Burge C.B., and Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120 (2005) 15-20
9. Krek A., Grün D., Poy M.N., Wolf R., Rosenberg L., Epstein E.J., MacMenamin P., da Piedade I., Gunsalus K.C., Stoffel M., et al. Combinatorial microRNA target predictions. Nat Genet 37 (2005) 495-500
10. John B., Enright A.J., Aravin A., Tuschl T., Sander C., and Marks D.S. Human MicroRNA targets. PLoS Biol 2 (2004) e363
11. Kiriakidou M., Nelson P.T., Kouranov A., Fitziev P., Bouyioukos C., Mourelatos Z., and Hatzigeorgiou A. A combined computational-experimental approach predicts human microRNA targets. Genes Dev 18 (2004) 1165-1178
12. Johnson S.M., Grosshans H., Shingara J., Byrom M., Jarvis R., Cheng A., Labourier E., Reinert K.L., Brown D., and Slack F. RAS is regulated by the let-7 microRNA family. Cell 120 (2005) 635-647
13. He L., Thomson J.M., Hemann M.T., Hernando-Monge E., Mu D., Goodson S., Powers S., Cordon-Cardo C., Lowe S.W., Hannon G.J., et al. A microRNA polycistron as a potential human oncogene. Nature 435 (2005) 828-833
14. Felli N., Fontana L., Pelosi E., Botta R., Bonci D., Facchiano F., Liuzzi F., Lulli V., Morsilli O., Santoro S., et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor downmodulation. Proc Natl Acad Sci U S A 102 (2005) 18081-18086
15. Galardi S., Mercatelli N., Giorda E., Massalini S., Frajese G.V., Ciafrè S.A., and Farace M.G. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27kip1. J Biol Chem 282 (2007) 23716-32372
16. Fitzgerald K. RNAi versus small molecules: different mechanisms and specificities can lead to different outcomes. Curr Opin Drug Discov Dev 8 (2005) 557-566
17. Rajewsky N., and Socci N.D. Computational identification of microRNA targets. Dev Biol 267 (2004) 529-535
18. Zhu S., Wu H., Wu F., Nie D., Sheng S., and Mo Y.Y. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 18 (2008) 350-359
19. Garofalo M., Quintavalle C., Di Leva G., Zanca C., Romano G., Taccioli C., Liu C.G., Croce C.M., and Condorelli G. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 27 (2008) 3845-3855
20. Xu C., Lu Y., Pan Z., Chu W., Luo X., Lin H., Xiao J., Shan H., Wang Z., and Yang B. The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci 120 (2007) 3045-3052. This study reveals a novel and interesting aspect of cellular functions of the muscle-specific miRNAs, miR-1 and miR-133, that is, regulation of apoptosis and survival in cardiomyocytes. Interestingly, they produce opposed effects: miR-1, by repressing HSP60 and HSP70 acts as a pro-apoptotic miR, whereas miR-133 by targeting Casp9 acts as anti-apoptotic miR, suggesting a possible role of relative miR-1 and miR-133 levels in regulating the cell fate.
21. Johnnidis J.B., Harris M.H., Wheeler R.T., Stehling-Sun S., Lam M.H., Kirak O., Brummelkamp T.R., Fleming M.D., and Camargo F.D. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 451 (2008) 1125-1129
22. Bhattacharyya S.N., Habermacher R., Martine U., Closs E.I., and Filipowicz W. Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell 125 (2006) 1111-1124
23. Lovis P., Gattesco S., and Regazzi R. Regulation of the expression of components of the exocytotic machinery of insulin-secreting cells by microRNAs. Biol Chem 389 (2008) 305-312
24. Pedersen I.M., Cheng G., Wieland S., Volinia S., Croce C.M., Chisari F.V., and David M. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449 (2007) 919-922. This study offers a new model of the host defense mechanism that exists in mammalian cells and adds a new evidence for a direct transcription regulation of microRNA by an endogenous ligand such as interferon.
25. Makeyev E.V., Zhang J., Carrasco M.A., and Maniatis T. The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol Cell 27 (2007) 435-448
26. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., Aldler H., Rattan S., Keating M., Rai K., et al. Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99 (2002) 15524-15529
27. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., Stephens R.M., Okamoto A., Yokota J., Tanaka T., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9 (2006) 189-198. This is the first study that identifies a unique profile of microRNA that discriminates lung cancers from non-cancerous tissues. Five microRNAs (miR-155, miR-17-3p, let-7a, miR-145 and miR-21) are deregulated in tumors. Moreover, high expression levels of miR-155 and low expression levels of let-7a correlate with poor patients survival.
28. Costinean S., Zanesi N., Pekarsky Y., Tili E., Volinia S., Heerema N., and Croce C.M. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 103 (2006) 7024-7029. Using a transgenic mouse model, the authors show that overexpression of miR-155 in B cells induces a preleukemic pre-B-cell proliferation, followed by high grade lymphoma pre-B leukemia. This is the first evidence that a miRNA by itself can induce a neoplastic disease.
29. Wang W.X., Rajeev B.W., Stromberg A.J., Ren N., Tang G., Huang Q., Rigoutsos I., and Nelson P.T. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci 28 (2008) 1213-1223
30. Lukiw W.J. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport 18 (2007) 297-300. This study indicates a different expression of microRNAs in fetal hippocampus, in aged brain and in Alzheimer hippocampus, revealing that microRNAs profiling is of importance for the prognosis of this and other diseases with important implication in the clinical setting.
31. Kim J., Inoue K., Ishii J., Vanti W.B., Voronov S.V., Murchison E., Hannon G., and Abeliovich A. A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317 (2007) 1220-1224
32. Bilen J., Liu N., and Bonini N.M. A new role for microRNA pathways: modulation of degeneration induced by pathogenic human disease proteins. Cell Cycle 5 (2006) 2835-2838
33. Lin S.L., Chang S.J., and Ying S.Y. First in vivo evidence of microRNA induced fragile X mental retardation syndrome. Mol Psychiatry 11 (2006) 616-617. This study is the first in vivo evidence of microRNAs implication in X fragile syndrome using a zebrafish model, raising hope for future therapies, based on microRNAs, in this disease.
34. Perkins D.O., Jeffries C.D., Jarskog L.F., Thomson J.M., Woods K., Newman M.A., Parker J.S., Jin J., and Hammond S.M. microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol 8 (2007) R27. By analyzing miRNA profiles, for the first time, in postmortem prefrontal cortex from schizophrenia patients, this study implicates a role for miRNAs in this disease, showing that 16 miRNAs are differentially expressed in prefrontal cortex of patient subjects compared with the psychiatrically unaffected comparison subjects.
35. Chang J., Nicolas E., Marks D., Sander C., Lerro A., Buendia M.A., Xu C., Mason W.S., Moloshok T., Bort R., et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 1 (2004) 106-113
36. Eisenberg I., Eran A., Nishino I., Moggio M., Lamperti C., Amato A.A., Lidov H.G., Kang P.B., North K.N., Mitrani-Rosenbaum S., et al. Distinctive patterns of microRNA expression in primary muscular disorders. Proc Natl Acad Sci U S A 104 (2007) 17016-17021
37. Carè A., Catalucci D., Felicetti F., Bonci D., Addario A., Gallo P., Bang M.L., Segnalini P., Gu Y., Dalton N.D., et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 13 (2007) 613-618. This study indicates a key role for miR-133 in the regulation of cardiac hypertrophy. In vivo, miR-133 levels are downmodulated not only in murine models of cardiac hypertrophy, but also in human disease associated with myocardial hypertrophy. More importantly, the effects of antagomir-133 on hypertrophy imply that modulation of miR-133 expression, by oligonucleotide administration, may have future therapeutic application in the clinical setting.
38. Yang B., Lin H., Xiao J., Lu Y., Luo X., Li B., Zhang Y., Xu C., Bai Y., Wang H., et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 13 (2007) 486-491
39. Tavazoie S.F., Alarcón C., Oskarsson T., Padua D., Wang Q., Bos P.D., Gerald W.L., and Massagué J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451 (2008) 147-152
40. Asangani I.A., Rasheed S.A., Nikolova D.A., Leupold J.H., Colburn N.H., Post S., and Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27 (2007) 2128-2136
41. Huang Q., Gumireddy K., Schrier M., le Sage C., Nagel R., Nair S., Egan D.A., Li A., Huang G., Klein-Szanto A.J., et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 10 (2008) 202-210
42. Calin G.A., and Croce C.M. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 66 (2006) 7390-7394
43. Johnson S.M., Grosshans H., Shingara J., Byrom M., Jarvis R., Cheng A., Labourier E., Reinert K.L., Brown D., and Slack F.J. RAS is regulated by the let-7 microRNA family. Cell 120 (2005) 635-647
44. Kumar M.S., Erkeland S.J., Pester R.E., Chen C.Y., Ebert M.S., Sharp P.A., and Jacks T. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A 105 (2008) 3903-3908. This study describes a case of miRNA family functioning as a tumor suppressor, in vivo, with clinically relevant predictions related to the use of let-7-based therapeutic agents in NSCLC.
45. Petrocca F., Visone R., Onelli M.R., Shah M.H., Nicoloso M.S., de Martino I., Iliopoulos D., Pilozzi E., Liu C.G., Negrini M., et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 13 (2008) 272-286. This study shows that miR-106b-25 cluster overexpression causes a decreased response of gastric cancer cells to TGF-β. miR-106b-25 cluster acts as an onco-miR, by interfering with the synthesis of p21 and Bim, contributing to the onset of TGF-β resistance in cancer cells and representing a novel therapeutic target for the treatment of gastric cancer.
46. Ma L., Teruya-Feldstein J., and Weinberg R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449 (2007) 682-688
47. Calin G.A., Liu C.G., Sevignani C., Ferracin M., Felli N., Dumitru C.D., Shimizu M., Cimmino A., Zupo S., Dono M., et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 101 (2004) 11755-11760
48. Xiao J., Yang B., Lin H., Lu Y., Luo X., and Wang Z. Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. J Cell Physiol 212 (2007) 285-292. This is the first study that shows a promising approach to prevent the lack of specificity of miRNA action. By using HCN2 and HCN4 isoforms, targeted by miR-1 and miR-133, they demonstrate the possibility of interference with miRNA action in a gene-specific manner.
49. Corsten M.F., Miranda R., Kasmieh R., Krichevsky A.M., Weissleder R., and Shah K. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res 67 (2007) 8994-9000
50. Yang H., Kong W., He L., Zhao J.J., O'Donnell J.D., Wang J., Wenham R.M., Coppola D., Kruk P.A., Nicosia S.V., et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68 (2008) 425-433
51. Salter K.H., Acharya C.R., Walters K.S., Redman R., Anguiano A., Garman K.S., Anders C.K., Mukherjee S., Dressman H.K., Barry W.T., et al. An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS ONE 3 (2008) e1908
52. Blower P.E., Verducci J.S., Lin S., Zhou J., Chung J.H., Dai Z., Liu C.G., Reinhold W., Lorenzi P.L., Kaldjian E.P., et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 6 (2007) 1483-1491
53. Mishra P.J., Humeniuk R., Mishra P.J., Longo-Sorbello G.S., Banerjee D., and Bertino J.R. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci U S A 104 (2007) 13513-13518. This study reports the relationship between a naturally occurring miRSNP (single nucleotide polimorphism) and drug resistance. In particular miR-24, regulates expression of the dihydrofolate reductase (DHFR) gene by binding to DHFR 3′UTR. A SNP in DHFR 3′UTR is associated with a loss of miR-24 function, enzyme overproduction, and methotrexate (MTX) resistance. These findings raise the possibility that miR-24 mimetics may be of value, alone or in combination with MTX, in the treatment of human disease.